• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

En­tra­da picks Syn­tim­mune vet Mario Saltarel­lo as CMO; Gene ther­a­py mak­er Or­chard hires Ran Zheng as CTO

7 years ago
Peer Review

Hack­ing in­to macrophage at­tack cir­cuits, Stan­ford sci­en­tists pitch a bet­ter ear­ly-warn­ing alert sys­tem for tu­mors

7 years ago
Discovery

No­var­tis' Al­con unit set for Swiss/NYSE de­but on April 9; Novo's keen­ly an­tic­i­pat­ed oral GLP-1 sub­mit­ted for speedy ...

7 years ago
News Briefing

Bone-mar­row fo­cused Ima­go Bio­Sciences scores $40M in Omega-led round

7 years ago
Financing
Startups

Af­ter land­ing a his­toric FDA OK, Al­ny­lam chief John Maraganore scores a big raise

7 years ago
People

Lit­tle Cona­tus' No­var­tis-part­nered liv­er drug suf­fers third straight de­feat, but CEO Men­to is still hold­ing out hope

7 years ago
People
R&D

RIP amy­loid be­ta the­o­ry? Nope. Bio­gen part­ner launch­es a new PhI­II be­fore ad­u­canum­ab's corpse turned cold

7 years ago
Bioregnum
Opinion

J&J mops up $900M in waste, writ­ing off the last big chunk of the $1.75B it spent to ac­quire Alios

7 years ago
Deals

Shang­hai-based can­cer drug­mak­er Ab­bisko lines up $42M B round as it makes a leap for the clin­ic

7 years ago
Financing
China

Hard-charg­ing GSK re­search chief Hal Bar­ron touts im­proved an­ti-BC­MA da­ta, aim­ing for fast ap­pli­ca­tions

7 years ago
R&D

$757M and 5 years lat­er, Cel­gene aban­doned a biotech part­ner, trig­ger­ing lay­offs

7 years ago
People
R&D

Found­ing For­ma CEO Steve Tre­gay fol­lows 61 staffers out the ex­it, re­placed by Genen­tech strat­e­gy vet

7 years ago
People

Feng Zhang, heavy­weight col­lab­o­ra­tors un­veil lat­est CRISPR up­start — a di­ag­nos­tic com­pa­ny

7 years ago
Startups

Roivan­t's rare dis­ease shop cap­tures FDA des­ig­na­tions; Chi­na biotech lands $18M launch round

7 years ago
News Briefing

Brex­it who? Record in­vest­ment last year fu­els big spike in reg­is­tered UK biotech firms

7 years ago
Financing
R&D

Bil­lion­aire Bertarel­li's Way­point steers al­ler­gy drug­mak­er Stal­ler­genes Greer pri­vate in $832M buy­out deal

7 years ago
Deals

As gener­ic en­try looms for its cash cow, Jazz wins FDA nod for fol­low-up sleep dis­or­der drug

7 years ago
Pharma

Bio­gen's Alzheimer's drug ad­u­canum­ab im­plodes in a PhI­II dis­as­ter — putting them at a per­ilous cross­roads

7 years ago
R&D

Faster, cheap­er, bet­ter? Post-buy­out deal Cel­gene jumps in­to AI al­liance with a $25 mil­lion bet on speed­ing dis­cov­ery ...

7 years ago
AI

NASH drug in hand, Mer­ck forges ahead with 2-year ex­ten­sion of NGM Bio col­lab­o­ra­tion deal

7 years ago
R&D
Pharma

To tack­le soar­ing pre­scrip­tion drug costs, Cana­da cre­ates new agency to ne­go­ti­ate prices; DMC clears phI­II test­ing of ...

7 years ago
News Briefing

EMA sounds its own safe­ty alarm for Pfiz­er block­buster, but they’re al­so not forc­ing a lim­it on dos­ing — yet

7 years ago
Pharma

With eye on rev­enue sta­bi­liza­tion, Gilead takes 4.9% hike on a bas­ket of drugs

7 years ago
Pharma

Flag­ship ties up a mon­ster $824M fund to back a new wave of biotech star­tups seed­ed in their lab

7 years ago
Financing
First page Previous page 949950951952953954955 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.